Company profile for Ambrx Inc

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Ambrx®, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophy...
Ambrx®, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties. We call this process Protein Medicinal Chemistry™. Protein Medicinal Chemistry™ can optimize any protein or antibody to create potentially best-in-class therapeutics.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
10975 North Torrey Pines Road La Jolla, CA 92037
Telephone
Telephone
(858) 875-2400
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20240307764175/en

BUSINESSWIRE
07 Mar 2024

https://www.fiercebiotech.com/biotech/jj-sees-deal-opportunities-neuroscience-and-immunology-post-ambrx-buy

FIERCE BIOTECH
23 Jan 2024

https://www.cnbc.com/2024/01/08/jj-to-acquire-ambrx-biopharma-a-cancer-drug-developer.html

CNBC
09 Jan 2024
Ambrx Announces Sale to Johnson & Johnson
Ambrx Announces Sale to Johnson & Johnson

08 Jan 2024

// GLOBENEWSWIRE

https://www.globenewswire.com//news-release/2024/01/08/2805344/0/en/Ambrx-Announces-Sale-to-Johnson-Johnson.html

GLOBENEWSWIRE
08 Jan 2024

https://www.globenewswire.com//news-release/2023/10/23/2764675/0/en/Ambrx-Announces-ARX517-a-PSMA-Targeted-ADC-Demonstrates-a-Promising-52-PSA50-50-Reduction-and-a-Highly-Differentiated-Safety-and-PK-Profile-in-Patients-with-mCRPC-who-Progressed-on.html

GLOBENEWSWIRE
23 Oct 2023
Ambrx's 'reset' arrives at the last line of prostate cancer
Ambrx's 'reset' arrives at the last line of prostate cancer

22 Oct 2023

// Annalee Armstrong FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/esmo-ambrxs-reset-arrives-last-line-prostate-cancer-offering-not-one-serious-adverse-event

Annalee Armstrong FIERCE BIOTECH
22 Oct 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Contact Ambrx Inc and get a quotation

Ambrx Inc is a supplier offers 1 products (APIs, Excipients or Intermediates).

Find a price of AS269 (A SYNTHETIC SMALL MOLECULE TOXIN WITH A HYDROXYLAMINE LINKER) bulk with DMF offered by Ambrx Inc

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty